WOBURN, Mass.--(BUSINESS WIRE)--Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, recently announced that during the quarter ending March 2014, dose sales of SIR-Spheres® microspheres grew 25.8 percent in the Americas region compared to the previous corresponding period. Globally, Sirtex has now achieved 39 consecutive quarters of does sales growth.
“We are very pleased with the third quarter results for the Americas,” said Mike Mangano, president of Sirtex Medical Inc. “Strong interest in SIR-Spheres microspheres is demonstrated within the interventional radiology community as we continue to open new treatment sites. The sustained momentum is aided by growing enthusiasm in the referring oncology community, which is beginning to recognize the treatment’s significant value for patients who often have very few choices.”
Over the next year, patient and physician education will remain a key focus as the company prepares for preliminary results from the landmark SIRFLOX study. The study completed enrollment in April 2013 and is aimed at demonstrating the effectiveness of SIR-Spheres microspheres as an earlier standard of care for colorectal cancer patients with liver metastases.
For more information visit www.Sirtex.com or find the latest updates on the SIR-Spheres microspheres Facebook page (www.Facebook.com/SIRSpheresmicrospheres).
About Selective Internal Radiation Therapy using SIR-Spheres microspheres
Selective Internal Radiation Therapy (SIRT), also known as radioembolization, is a proven technology for inoperable liver cancer that delivers doses of radiation directly to the site of tumors. In a minimally invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.
Clinical studies have confirmed that patients with metastatic colorectal cancer treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone.
In the U.S., SIR-Spheres microspheres are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). SIR-Spheres microspheres are approved for use in Argentina, Brazil, Australia, the European Union and several countries in Asia for the treatment of unresectable liver tumors.
Available at more than 700 treatment centers, over 40,000 doses of SIR-Spheres microspheres have been supplied worldwide.
For more information, visit www.sirtex.com.
SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.
